Vascepa
Manufacturing · New Jersey, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
1430 Rte 206, Bedminster, New Jersey, 07...Website
www.vascepa.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Vascepa
Amarin Pharma, Inc. offers VASCEPA® (icosapent ethyl), a prescription medication designed to reduce the risk of heart attack, stroke, and other cardiovascular issues in adults, particularly those with diabetes and multiple risk factors. The company provides various resources for healthcare professionals and patients, including information on cardiovascular risk and heart health tips. Their target clients are adults with cardiovascular disease or at risk, as well as healthcare providers seeking effective treatment options. Amarin also emphasizes savings programs for eligible patients to make the medication more accessible.Explore more
Popular SearchesVascepaAmarin Pharma IncVascapaSIC Code 28,283NAICS Code 32,325Show moreSell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Vascepa your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Vascepa is spiking on competitors!
Click to see if Vascepa had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Vascepa
Check if Vascepa has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Vascepa launches new products
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Vascepa has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Vascepa recently announced quarterly report
Vascepa, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Vascepa
Compare insights from companies similar to Vascepa, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Vascepa
<$5M
11-50
Private
-
2013
N/A
Company Profile Activity
Activity Insights
Vascepa is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Vascepa is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Vascepa.
Vascepa Tech Stack
A closer look at the technologies used by Vascepa
Vascepa News & Media
New REDUCE-IT® Aspirin Analysis Presented at AHA Scientific Sessions 2025 Reinforces VASCEPA®/VAZKEPA® (Icosapent Ethyl) Reduced Cardiovascular Events in High-Risk Patients
DUBLIN and BRIDGEWATER, N.J., Nov. 09, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company committed to advancing the science of cardiovascular care, today highlighted a new post hoc analysis of aspirin use in REDUCE-IT® reinforcing that icosapent ethyl significantly reduced cardiovascular (CV) events in high-risk patients. These findings highlight the importance of guideline-directed therapies and further validate the role of icosapent ethyl in comprehensive CV risk manageNew REDUCE-IT® Analyses Presented at ESC 2025 Include Data Showing VASCEPA®/VAZKEPA® (Icosapent Ethyl) Therapy Resulted in 9% Fewer Total Hospitalizations & Reduces Cardiovascular Disease Risk in Certain High-Risk Patient Subgroups
-- 2025 ESC/EAS Dyslipidemia Guideline Focused Update Reaffirms High Dose Icosapent Ethyl as Class IIA Recommended Therapy in High-Risk or Very High-Risk Patients Based on REDUCE-IT -- DUBLIN and BRIDGEWATER, N.J., Aug. 30, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today highlighted three sub-analyses from the REDUCE-IT® trial describing the impact of VASCEPA®/VAZKEPA® (icosapent ethyl - IPE) administration on cardiovascular disease (CVD) risk associated with Cardiovascular-KInvestigators to Present New REDUCE-IT Subanalysis of VASCEPA®/VAZKEPA® (icosapent ethyl) in Patients With and Without Coronary Artery Disease History and Mechanistic Data on Eicosapentaenoic Acid (EPA) at the American Heart Association’s (AHA) Annual Scientific Sessions
DUBLIN and BRIDGEWATER, N.J., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that investigators will present an additional subgroup analysis from the landmark REDUCE-IT outcomes trial in patients with and without coronary artery disease (CAD) history and mechanistic data on eicosapentaenoic acid (EPA) at the American Heart Association’s Scientific Sessions, November 16-18, 2024 in Chicago, IL.Research Highlighting the Clinical Impact of VASCEPA®/VAZKEPA (icosapent ethyl) in Patients with Diabetes and High Cardiovascular Risk and the Anti-Lp(a) Oxidation Mechanistic Effect of Eicosapentaenoic Acid (EPA) to be Presented at the 60th Annual European Association for the Study of Diabetes (EASD) Meeting
DUBLIN, Ireland and BRIDGEWATER, N.J., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that new supported and/or funded research on the clinical impact of VASCEPA®/VAZKEPA (icosapent ethyl) in patients with diabetes and high cardiovascular risk and the anti-Lp(a) oxidation mechanistic effects of eicosapentaenoic acid (EPA) will be presented at the 60th Annual European Association for the Study of Diabetes (EASD) Meeting September 9 – 13, 2024 in Madrid, Sp
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Vascepa
Sign Up For FreeTo access detailed company insights
Amarin Pharma, Inc. offers VASCEPA® (icosapent ethyl), a prescription medication designed to reduce the risk of heart attack, stroke, and other cardiovascular issues in adults, particularly those with diabetes and multiple risk factors. The company provides various resources for healthcare professionals and patients, including information on cardio... Read More
